Stock comparison
IDEXX Laboratories
Veeva Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
VEEV
Veeva Systems
Market cap
$26.07B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | VEEV | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 66B | IDXX |
| Benjamin Graham | 80A | 81A | VEEV |
| Philip Fisher | 75B | 77B | VEEV |
| Peter Lynch | 71B | 60C | IDXX |
| Joel Greenblatt | 83C | 52C | IDXX |
| Charlie Munger | 87A | 62C | IDXX |
| Terry Smith | 84A | 65D | IDXX |
Side-by-side metrics
| Metric | IDXX | VEEV |
|---|---|---|
| Market cap | $44.06B | $26.07B |
| P/E (TTM) | 39.0x | 28.7x |
| EV/EBIT | 31.6x | 26.9x |
| ROIC (TTM) | 40.66% | 9.48% |
| Gross margin | 62.05% | 75.53% |
| Net margin | 24.63% | 28.44% |
| Revenue CAGR 5y | 7.56% | 14.63% |
| EPS CAGR 5y | 10.79% | 18.76% |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 9.48%+77%
- Market cap$44.06Bvs $26.07B+41%
VEEV leads on
- Debt / Equity0.0xvs 0.7x+98%
- Revenue CAGR 5y14.63%vs 7.56%+48%
- EPS CAGR 5y18.76%vs 10.79%+42%
- P/E (TTM)28.7xvs 39.0x+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.